Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patientsJoseph Gligorov, Luis Matamala, Beyhan Ataseven et al.|European Journal of Cancer|2017Cited by 47
CCND1 POLYMORPHISM AND RISK OF NSCLC IN SMOKERSLihua Song, Kwun M. Fong, Annalese Semmler et al.|Unknown|2003Cited by 0